More about
Cd19-Positive Tumor
News
July 09, 2020
2 min read
Save
FDA clears IND application for stem cell-derived CAR-T targeting CD19-positive tumors
The FDA cleared an investigational new drug application for FT819, a chimeric antigen receptor T-cell therapy for the treatment of CD19-positive tumors, according to a press release from the agent’s manufacturer.